Mutares to Propose Capital Increase and 25% Annual Growth Plan at July AGM

Mutares shares test key technical level while management unveils aggressive growth plan, new Chemicals & Materials segment, and equity raise to fund global expansion and debt reduction.

The shares of Munich-based holding company Mutares closed Friday at €26.95, down 0.19% on the day and sitting precisely on their 50-day moving average — a clean technical test heading into the new week. The stock has clawed back 9.11% over the past 30 days and gained 2.28% on the week, but remains 9.87% lower since January and 20.27% below the level of a year ago. The relative strength index of 52.3 signals neutral momentum, and the shares still trade 7.42% under their 200-day moving average, leaving room for a potential upside without any clear technical tailwind.

Beyond the chart, management is laying out a long-term transformation plan that hinges on aggressive growth. Mutares targets average annual group revenue expansion of at least 25% through 2030, with the holding company’s net profit expected to rise at a similar clip. To make that ambition stick, the firm is branching into new territory — the newly created “Chemicals & Materials” segment opens a fresh industry lane for carve-out deals, while new offices, including one in India, are designed to improve access to acquisition opportunities outside Europe. The aim is to shift from a largely European player to a more globally diversified holding company.

Funding that expansion will require additional equity firepower. At the annual general meeting in July, the board will ask shareholders to approve “Authorized Capital 2026/I,” permitting the issuance of up to roughly 4.15 million new shares. The authorization allows both cash and in-kind contributions, giving Mutares the flexibility to move quickly when attractive deals surface. A parallel statutory change would enable the issuance of electronic shares, cutting administrative costs and modernizing transferability.

The capital increase plan comes alongside an ambitious deleveraging effort. Bond liabilities are targeted to drop from around €385 million to a range of €250 million to €300 million, funded by proceeds from portfolio sales. That timetable dovetails with scheduled covenant checks in June — a periodic stress test for the balance sheet. The fresh equity authorization provides an extra buffer should Mutares need to act without tapping the bond markets.

For fiscal 2026, management is holding to its existing outlook. Group revenue is forecast between €7.9 billion and €9.1 billion, while the holding company’s net profit is seen at €165 million to €200 million. The main drivers remain profitable exits of matured portfolio companies and the expected closing of the SABIC acquisition in the second quarter.

The July shareholder meeting in Munich will also cover routine items including the discharge of the board and the election of PricewaterhouseCoopers GmbH as the new auditor. But the spotlight will be on the capital authorization and whether investors endorse the growth roadmap. The stock’s distance from its 52-week high of €36.75 underscores the skepticism that still surrounds the shares.

For the near term, the price zone around €26.95 serves as a short-term gauge, while the unchanged guidance sets the fundamental rhythm. Management’s message is clear: growth alone is not enough — the market wants proof that the larger platform can reliably deliver earnings contributions. The July vote will show whether shareholders are willing to provide the ammunition Mutares needs to keep pursuing its consolidation strategy.